Faricimab

Indication

Treating visual impairment caused by macular oedema after retinal vein occlusion (NICE TA1004)

NICE TA1004 - Faricimab for treating visual impairment caused by macular oedema after retinal vein occlusion

Red

Brand:

Nice TA:

1004

Commissioning responsibility:

CCG

PbR excluded:

Yes

BNF chapter:

Eye

Background

1.1 Faricimab is recommended, within its marketing authorisation, as an option for treating visual impairment caused by macular oedema after central or branch retinal vein occlusion in adults. It is only recommended if the company provides it according to the commercial arrangement.

Recommendation

LSCMMG Recommendation:

Red

Reason for decision:

Specialist medicine

Supporting documents:

Decisions of Lancashire local decision making groups

BwD	BP	CSR	EL	FW	GP	MB	WL
Red	Red	Red	Red	Red	Red	Red	Red

What do the colours mean?

Last Updated: 13 - Nov - 2024

Breadcrumb

Faricimab

Indication

Background

Recommendation

Decisions of Lancashire local decision making groups